ORBCEL™ for Diabetic Foot Ulcers
Diabetic Foot Ulcers (DFU)
Pre-clinical/ResearchActive
Key Facts
Indication
Diabetic Foot Ulcers (DFU)
Phase
Pre-clinical/Research
Status
Active
Company
About Orbsen Therapeutics
Orbsen Therapeutics is a private, clinical-stage biotech developing immunomodulatory cell therapies for serious conditions with high unmet need, including Diabetic Kidney Disease (DKD) and Acute Respiratory Distress Syndrome (ARDS). Its lead candidate, ORBCEL™, is a purified MSC therapy designed to target specific immune pathways driving inflammation and fibrosis. The company has advanced ORBCEL™ into Phase 2 clinical trials, supported by significant non-dilutive EU grant funding, and is actively fundraising to progress its pipeline. Orbsen operates from a new headquarters in Galway, positioning itself at the forefront of next-generation cell therapy.
View full company profileTherapeutic Areas
Other Diabetic Foot Ulcers (DFU) Drugs
| Drug | Company | Phase |
|---|---|---|
| Intralesional rhEGF (Heberprot-P related) | Discovery Therapeutics Caribe | Phase 3 |
| Nanordica® Advanced Antibacterial Wound Dressing | Nanordica Medical | Phase 2/3 |
| DeepView Wound Imaging System | Spectral AI | Unknown |
| ABCB5+ MSCs | RHEACELL | Pre-clinical development |